It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: MystikMushroom
a reply to: DigitalJedi805
The website looks like something they'd assign to high school IT intern...
This is like hearing about a gourmet pizza place, where one can't get a reservation....and then finding out it's a Chuck-E-Cheese's.
originally posted by: marg6043
a reply to: aboutface
That is the point I am trying to make and bring on, If ZMapp was soo successful with the people that it was administered to, why is now delays in production? a property spat? lord have mercy while people are dying by the thousands, it makes no sense.
Is outright criminal. It could be that those with the money and power are taking care of themselves first.
originally posted by: DigitalJedi805
If you're going to get granted [millions?] from the federal government, you don't have your 14 year old son build the website. You spend $5000 and have a professional company build something presentable once...
originally posted by: Osiris1953
a reply to: DigitalJedi805
What do they need a nice website for? The general public?
If they don't have investors to worry about, they really don't care.
One is well-established British drug giant GlaxoSmithKline GSK, -0.13% , which is working on an Ebola vaccine in conjunction with the National Institute of Health’s National Institute of Allergy and Infectious Disease, or NIAID, unit. Glaxo’s story is well known: Nearly 100,000 employees, roughly $40 billion in annual sales. Profits, though diminishing a bit as it loses patent protection on some of its offerings, still are firmly in the black.
Japanese photographic company Fujifilm Holdings Corp. FUJIF, +0.17% , with nearly $20 billion in sales and $1 billion in annual profits. Japan’s equivalent to the U.S.’s Eastman Kodak KODK, +0.09% prior to the digital age, Fujifilm has diversified into chemicals, medical products and pharmaceuticals. Its Toyama Chemical Co. has been contracted out to test an anti-influenza drug on an Ebola patient.
Tekmira Pharmaceuticals Corp. TKMR, -1.12% : Tekmira has gotten the biggest stock boost of all the Ebola players as its therapy, TKM-Ebola, seems to be getting the most attention from regulators and investors. The company recorded $15.5 million in sales for fiscal 2013 and a loss of 87 cents a share. It has roughly 85 employees, according to one government web site.
BioCryst Pharmaceuticals Corp. BCRX, -0.47% : BioCryst also declined to comment, but the company is developing a therapy for NIAID, paralleling Glaxo’s vaccine work. Remember, its therapy is for already infected patients, while vaccines like those by Glaxo are used to prevent the disease.
originally posted by: DigitalJedi805
a reply to: PlasticWizard
I'm implying that this entire corporation is entirely fabricated.
By a 'Real' company - I mean one that actually exists and produces things.
I'm not bashing anyone; I'm just asking for proof that they are doing what they say - as I have yet to see any.
originally posted by: PlasticWizard
originally posted by: DigitalJedi805
a reply to: PlasticWizard
I'm implying that this entire corporation is entirely fabricated.
By a 'Real' company - I mean one that actually exists and produces things.
I'm not bashing anyone; I'm just asking for proof that they are doing what they say - as I have yet to see any.
They made zmapp. It was successful and They ran out. Grant money and research doc for more went to the bidders who promised more vaccines for less money and turnaround time .
And bashing the company based on Web design that most likely cost 5k at the time (over 10 yrs ago) is exactly what you did.
Questions remain over why a made-in-Canada experimental Ebola vaccine is still sitting in a Winnipeg laboratory instead of being dispensed in West Africa, with a scientific journal suggesting that an intellectual property dispute may be to blame.
It's been more than six weeks since the Canadian government promised to donate the vaccine to the international community to help fight the ongoing Ebola outbreak.
About 800 to 1,000 doses of the vaccine, which was developed at the National Microbiology Laboratory in Winnipeg, are supposed to be shipped to West Africa.
The federal government has said the delay is with the World Health Organization, which is helping to determine who should get the vaccine and how to ship the doses properly.
But a story published this week on ScienceInsider, a news website of the journal Science, raises the theory that a U.S.-based company that purchased a licence to the vaccine's commercialization from the federal government is "dragging its feet."
The article by Berlin-based journalist Kai Kupferschmidt cites scientists who are concerned that NewLink Genetics is "worried about losing control over the development of the vaccine."
originally posted by: DigitalJedi805
originally: PlasticWizard
originally posted by: DigitalJedi805
a reply to: PlasticWizard
I'm implying that this entire corporation is entirely fabricated.
By a 'Real' company - I mean one that actually exists and produces things.
I'm not bashing anyone; I'm just asking for proof that they are doing what they say - as I have yet to see any.
They made zmapp. It was successful and They ran out. Grant money and research doc for more went to the bidders who promised more vaccines for less money and turnaround time .
And bashing the company based on Web design that most likely cost 5k at the time (over 10 yrs ago) is exactly what you did.
So... You mean to tell me, that this company last for ten years - produced One product that Just became necessary, and then ran out of it in under a month?
If you think that this website cost $5k - Ever - you've neither designed a website, nor had one designed for you. This website, is not something you pay for. This is something someone in college gets a C- on.
originally posted by: MystikMushroom
One would think if you've saved lives from Ebola in the recent past, you'd want to beef up your website a little bit for curious media and news people. I mean, having it work on a few people is really good PR, and no doubt the media and possibly other (larger) companies would take note and be curious...?
DEFENSE THREAT REDUCTION AGENCY
Mapp Biopharmaceutical, Inc, San Diego, California, is being awarded an $8,152,103 cost- plus-fixed-fee contract for the development of a broad-spectrum monoclonal cocktail for prevention of VEEV, WEEV and EEEV, in support of the research and development enterprise. Work will be performed in San Diego, California, and various subcontractor locations; work is expected to be completed May 2017. Bids were solicited and nine were received. The contracting activity is Defense Threat Reduction Agency, Fort Belvoir, Virginia (HDTRA1-14-C-0115).
"In 1990 and 1991, we engineered a smallpox at Vector. It was found that several areas of the smallpox genome" -- the DNA -- "can be used for the introduction of some foreign genetic material. The first development was smallpox and VEE. VEE, or Venezuelan equine encephalitis, is a brain virus. It causes a severe headache and near-coma, but it is generally not lethal. Alibek said that the researchers spliced VEE into smallpox.
More recently, Alibek claims, the Vector researchers may have created a recombinant Ebola-smallpox chimera. One could call it Ebolapox. Ebola virus uses the molecule RNA for its genetic code, whereas smallpox uses DNA.